Notably, epidermal growth factor receptor (EGFR) is reported to be overexpressed in osteosarcoma and, for that reason, is targeted by a human EGFR antibody conjugated to our novel targeted multifunctional radio-nanotherapeutic [51]. Here, EGFR is linked to osteosarcoma.